Maria Dobek - Jan 2, 2025 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role: Vice President, Accounting
Signature: /s/ James Pennington, Attorney-in-Fact
Stock symbol: JANX
Transactions as of: Jan 2, 2025
Transactions value $: $0
Form type: 4
Date filed: 1/3/2025, 08:10 PM
Previous filing: Aug 9, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JANX	Common Stock	Award	$0	+14K	+1400000%	$0.00	14K	Jan 2, 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JANX	Stock option (right to buy)	Award	$0	+31.5K		$0.00	31.5K	Jan 2, 2025	Common Stock	31.5K	$53.24	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026.
F2	Includes 1 share acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2024.
F3	25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period.